{"id":53821,"date":"2026-01-12T23:12:08","date_gmt":"2026-01-12T15:12:08","guid":{"rendered":"https:\/\/flcube.com\/?p=53821"},"modified":"2026-01-12T23:12:11","modified_gmt":"2026-01-12T15:12:11","slug":"noetik-enters-50m-ai-collaboration-with-gsk-licensing-octo-vc-virtual-cell-models-for-nsclc-and-crc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53821","title":{"rendered":"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC"},"content":{"rendered":"\n<p><strong><strong>Noetik<\/strong><\/strong>, an AI\u2011native biotech pioneering self\u2011supervised machine learning in cancer therapeutics, announced a <strong>five\u2011year strategic collaboration and AI model licensing agreement<\/strong> with <strong>GSK plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE:\u202fGSK<\/a>). The deal grants GSK a <strong>non\u2011exclusive license<\/strong> to Noetik\u2019s <strong>OCTO\u2011VC virtual cell foundation models<\/strong> for <strong>non\u2011small cell lung cancer (NSCLC)<\/strong> and <strong>colorectal cancer (CRC)<\/strong>, validating Noetik\u2019s platform as a scalable, revenue\u2011generating engine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Noetik (private) and GSK plc (NYSE:\u202fGSK)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>5\u2011year strategic collaboration + AI model licensing<\/td><\/tr><tr><td><strong>Licensed Technology<\/strong><\/td><td>OCTO\u2011VC virtual cell foundation models<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>NSCLC and CRC<\/td><\/tr><tr><td><strong>Exclusivity<\/strong><\/td><td>Non\u2011exclusive (GSK\u2011only in these indications)<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>8\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Additional Collaboration<\/strong><\/td><td>Bespoke human spatial dataset generation for strategic targets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile\">Technology Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> OCTO\u2011VC powered by the <strong>largest spatial biology dataset in oncology<\/strong>, specifically engineered for self\u2011supervised AI training<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Industry\u2011first <strong>virtual cell simulation technology<\/strong> that models tumor\u2011immune microenvironment interactions at single\u2011cell resolution<\/li>\n\n\n\n<li><strong>Application:<\/strong> Accelerates target identification, biomarker discovery, and combination therapy design by predicting cellular responses to novel perturbations<\/li>\n\n\n\n<li><strong>Data Scale:<\/strong> >10\u202fmillion spatially resolved tumor cells across 2,500+ patient samples from 15 cancer types<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Unlike traditional AI models trained on bulk transcriptomics, OCTO\u2011VC preserves spatial architecture, enabling mechanistic insights into immunosuppressive niches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount\/Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 50\u202fmillion (cash)<\/td><\/tr><tr><td><strong>Near\u2011Term Milestones<\/strong><\/td><td>Up to USD 25\u202fmillion (undisclosed triggers)<\/td><\/tr><tr><td><strong>Annual Licensing Fee<\/strong><\/td><td>Subscription\u2011based; estimated USD 18\u201122\u202fmillion\/year<\/td><\/tr><tr><td><strong>Total Deal Value (5\u2011year)<\/strong><\/td><td>Estimated USD <strong>165\u2011185\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Royalty\/Profit Share<\/strong><\/td><td>None; pure licensing + service model<\/td><\/tr><tr><td><strong>Validation<\/strong><\/td><td>First major platform\u2011licensing deal for Noetik, establishing recurring revenue base<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-impact\">Strategic Positioning &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Drug Discovery Market:<\/strong> Global spend projected to reach <strong>$5.3\u202fbillion by 2028<\/strong>; spatial biology\u2011driven platforms capturing 35\u202f% of segment growth<\/li>\n\n\n\n<li><strong>GSK\u2019s AI Strategy:<\/strong> Partnership complements GSK\u2019s <strong>in\u2011house AI center<\/strong> and the recent acquisition of <strong>Sierra Oncology<\/strong>, strengthening its immuno\u2011oncology pipeline<\/li>\n\n\n\n<li><strong>Noetik\u2019s Revenue Trajectory:<\/strong> Deal transforms Noetik from R&amp;D\u2011stage to <strong>revenue\u2011generating<\/strong>; projected <strong>2026 revenue of $68\u202fmillion<\/strong>, rising to <strong>$115\u202fmillion by 2028<\/strong> via GSK fees + additional partnerships<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Recursion Pharmaceuticals<\/strong> and <strong>Insilico Medicine<\/strong> focus on small\u2011molecule design, not spatial cell simulation<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Noetik\u2019s <strong>virtual cell<\/strong> approach is <strong>first\u2011in\u2011class<\/strong>, offering GSK a unique capability to model resistance mechanisms <em>in silico<\/em> before clinical trials<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> GSK\u2019s subscription commitment signals confidence in OCTO\u2011VC\u2019s predictive accuracy, potentially unlocking <strong>milestone\u2011based collaborations in melanoma and ovarian cancer<\/strong> by 2027<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h2>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding Noetik\u2019s revenue projections, GSK\u2019s utilization of OCTO\u2011VC, and expansion into additional indications. Actual results may differ due to model performance, competitive dynamics in AI\u2011driven drug discovery, and GSK\u2019s internal pipeline prioritization.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Noetik, an AI\u2011native biotech pioneering self\u2011supervised machine learning in cancer therapeutics, announced a five\u2011year strategic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,16,184,4548,914],"class_list":["post-53821","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-cancer","tag-gsk","tag-noetik","tag-nyse-gsk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Noetik, an AI\u2011native biotech pioneering self\u2011supervised machine learning in cancer therapeutics, announced a five\u2011year strategic collaboration and AI model licensing agreement with GSK plc (NYSE:\u202fGSK). The deal grants GSK a non\u2011exclusive license to Noetik\u2019s OCTO\u2011VC virtual cell foundation models for non\u2011small cell lung cancer (NSCLC) and colorectal cancer (CRC), validating Noetik\u2019s platform as a scalable, revenue\u2011generating engine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53821\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC\" \/>\n<meta property=\"og:description\" content=\"Noetik, an AI\u2011native biotech pioneering self\u2011supervised machine learning in cancer therapeutics, announced a five\u2011year strategic collaboration and AI model licensing agreement with GSK plc (NYSE:\u202fGSK). The deal grants GSK a non\u2011exclusive license to Noetik\u2019s OCTO\u2011VC virtual cell foundation models for non\u2011small cell lung cancer (NSCLC) and colorectal cancer (CRC), validating Noetik\u2019s platform as a scalable, revenue\u2011generating engine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53821\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T15:12:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T15:12:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53821#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53821\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC\",\"datePublished\":\"2026-01-12T15:12:08+00:00\",\"dateModified\":\"2026-01-12T15:12:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53821\"},\"wordCount\":472,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"Cancer\",\"GSK\",\"Noetik\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53821#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53821\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53821\",\"name\":\"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T15:12:08+00:00\",\"dateModified\":\"2026-01-12T15:12:11+00:00\",\"description\":\"Noetik, an AI\u2011native biotech pioneering self\u2011supervised machine learning in cancer therapeutics, announced a five\u2011year strategic collaboration and AI model licensing agreement with GSK plc (NYSE:\u202fGSK). The deal grants GSK a non\u2011exclusive license to Noetik\u2019s OCTO\u2011VC virtual cell foundation models for non\u2011small cell lung cancer (NSCLC) and colorectal cancer (CRC), validating Noetik\u2019s platform as a scalable, revenue\u2011generating engine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53821#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53821\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53821#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC - Insight, China&#039;s Pharmaceutical Industry","description":"Noetik, an AI\u2011native biotech pioneering self\u2011supervised machine learning in cancer therapeutics, announced a five\u2011year strategic collaboration and AI model licensing agreement with GSK plc (NYSE:\u202fGSK). The deal grants GSK a non\u2011exclusive license to Noetik\u2019s OCTO\u2011VC virtual cell foundation models for non\u2011small cell lung cancer (NSCLC) and colorectal cancer (CRC), validating Noetik\u2019s platform as a scalable, revenue\u2011generating engine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53821","og_locale":"en_US","og_type":"article","og_title":"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC","og_description":"Noetik, an AI\u2011native biotech pioneering self\u2011supervised machine learning in cancer therapeutics, announced a five\u2011year strategic collaboration and AI model licensing agreement with GSK plc (NYSE:\u202fGSK). The deal grants GSK a non\u2011exclusive license to Noetik\u2019s OCTO\u2011VC virtual cell foundation models for non\u2011small cell lung cancer (NSCLC) and colorectal cancer (CRC), validating Noetik\u2019s platform as a scalable, revenue\u2011generating engine.","og_url":"https:\/\/flcube.com\/?p=53821","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T15:12:08+00:00","article_modified_time":"2026-01-12T15:12:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53821#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53821"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC","datePublished":"2026-01-12T15:12:08+00:00","dateModified":"2026-01-12T15:12:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53821"},"wordCount":472,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","Cancer","GSK","Noetik","NYSE: GSK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53821#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53821","url":"https:\/\/flcube.com\/?p=53821","name":"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T15:12:08+00:00","dateModified":"2026-01-12T15:12:11+00:00","description":"Noetik, an AI\u2011native biotech pioneering self\u2011supervised machine learning in cancer therapeutics, announced a five\u2011year strategic collaboration and AI model licensing agreement with GSK plc (NYSE:\u202fGSK). The deal grants GSK a non\u2011exclusive license to Noetik\u2019s OCTO\u2011VC virtual cell foundation models for non\u2011small cell lung cancer (NSCLC) and colorectal cancer (CRC), validating Noetik\u2019s platform as a scalable, revenue\u2011generating engine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53821#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53821"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53821#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO\u2011VC Virtual Cell Models for NSCLC and CRC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53821"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53821\/revisions"}],"predecessor-version":[{"id":53825,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53821\/revisions\/53825"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}